<SEC-DOCUMENT>0001213900-14-004460.txt : 20140627
<SEC-HEADER>0001213900-14-004460.hdr.sgml : 20140627
<ACCEPTANCE-DATETIME>20140624160916
ACCESSION NUMBER:		0001213900-14-004460
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140624
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140624
DATE AS OF CHANGE:		20140624

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		14937590

	BUSINESS ADDRESS:	
		STREET 1:		501 FIFTH AVENUE, 3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		212-300-2131

	MAIL ADDRESS:	
		STREET 1:		501 FIFTH AVENUE, 3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k062414_actiniumpharma.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<html>
<head>
    <title>f8k062414_actiniumpharma.htm</title>
    <!--Licensed to: Edgar Agents LLC-->
    <!--Document Created using EDGARizerAgent 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FORM 8-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CURRENT REPORT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Section 13 or 15(d) of the</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date of Report (Date of earliest event reported): June 24, 2014</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="33%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">000-52446</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="33%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">88-0378336</font></div>
</td>
</tr><tr>
<td valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or other jurisdiction</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of&#160;incorporation)</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="32%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Commission</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">File Number)</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(IRS Employer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Identification No.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="66%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">501 Fifth Avenue, 3rd Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">New York, NY</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="33%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">10017</font></div>
</td>
</tr><tr>
<td valign="top" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Address of principal executive offices)</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Zip Code)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Registrant&#8217;s telephone number, including area code: <font style="DISPLAY: inline; FONT-WEIGHT: bold">(646) 459-4201</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="78%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Former name or former address, if changed since last report)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<font style="DISPLAY: inline; TEXT-DECORATION: underline">see</font> General Instruction A.2. below):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt">o</font></div>
</td>
<td align="left" valign="top" width="73%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt">o</font></div>
</td>
<td align="left" valign="top" width="73%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt">o</font></div>
</td>
<td align="left" valign="top" width="73%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt">o</font></div>
</td>
<td align="left" valign="top" width="73%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 8.01 Other Events.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Actinium Pharmaceuticals, Inc. (the "Company") issued a press release on June 24, 2014 announcing a proposed public offering of its common stock. A copy of the release is attached to this Form 8-K as Exhibit&#160;99.1.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 9.01 Financial Statements and Exhibits.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">(d) Exhibits. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exhibit&#160;99.1</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Press release of Actinium Pharmaceuticals, Inc. dated June 24, 2014</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="60%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dated: June 24, 2014</font></div>
</td>
<td align="left" colspan="2" valign="top" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>
</td>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="60%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="27%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="60%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="bottom" width="27%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Kaushik J. Dave&#160;</font></div>
</td>
<td align="left" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="60%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:&#160;&#160;Kaushik J. Dave</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:&#160;&#160;&#160;&#160;President and Chief Executive</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Officer</font></div>
</td>
<td align="left" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">3

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f8k062414ex99i_actiniumphar.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
    <title>f8k062414ex99i_actiniumphar.htm</title>
    <!--Licensed to: Edgar Agents LLC-->
    <!--Document Created using EDGARizerAgent 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-WEIGHT: bold">Exhibit 99.1</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><img src="logo.jpg" alt=""></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Actinium&#160;Pharmaceuticals,&#160;Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Actinium Announces Proposed Public Offering of Common Shares</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">NEW YORK, NY, June 24, 2014</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>&#8211; Actinium Pharmaceuticals, Inc. (&#8220;Actinium&#8221; or the &#8220;Company&#8221;) (NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers,&#160;&#160;today announced that it intends to offer shares of its common stock in an underwritten public offering.&#160;&#160;The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares are being offered by Actinium.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Canaccord Genuity Inc. is acting as sole book-running manager for the proposed offering and Laidlaw &amp; Company (UK) Ltd. is acting as lead manager.&#160;&#160;The Company expects to grant the underwriter a 30-day option to purchase up to an additional 15 percent of the number of common shares sold pursuant to the public offering solely to cover over-allotments, if any</font>.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The offering is being made pursuant to a shelf registration statement (File No. 333-194768) previously filed with and declared effective by the U.S. Securities and Exchange Commission (SEC).&#160;&#160;This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available free of charge on the website of the SEC at www.sec.gov.&#160;&#160;When available, copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained by contacting the Syndicate Department of Canaccord Genuity Inc., by mail at 99 High Street, 12th Floor, Boston, Massachusetts 02110, or by telephone at (800) 225-6201.&#160;&#160;Prospective investors should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that Actinium has filed with the SEC for more complete information about Actinium and the offering.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Actinium Pharmaceuticals</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Actinium Pharmaceuticals, Inc. (<font style="DISPLAY: inline; TEXT-DECORATION: underline">www.actiniumpharma.com</font>) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company&#8217;s lead radiopharmaceutical Iomab&#8482;-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab&#8482;-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company&#8217;s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Forward-Looking Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This news release contains &#8220;forward-looking statements&#8221; as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance, including the public offering of stock contemplated hereby. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. The risks and uncertainties in these forward-looking statements include, but are not limited to, the risks and uncertainties described in the section entitled &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2013, in the preliminary prospectus supplement and accompanying prospectus, and in its other filings from time to time filed with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of the Company&#8217;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contact:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Evan Smith, CFA, VP Investor Relations and Finance</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">+1 (646) 840-5442,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Email: esmith@actiniumpharma.com</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`#P`
M?@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/[^****`"BBC/\`G]/Y\4`!..:B,J;"[<(%+%FP%557<2S$[5`&
M<EB`,')`YK\,O^"DW_!:CX??L?ZUK_P-^".B:?\`&/\`:8TR"/\`MK3=2:_M
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M^7;!\#?B-K>D?\)/X0^`?Q2\3Z3>S7#/K_AWX0^-]:TR62$7"7LW]LV'@R\7
M5K6"T.RXNK?4AY,DTC)<P3PJ5V_AM\:/BO\``_6/[7^#WQ7^)GP?UWP]=.;*
MT\#>-M5\)7FF1W$49BTZ[\,7T4VF7>E07<5TDFG:]H=YI>KW'^DW5C&SO$L^
MT?9+YW_"R_,345]I_))KI_>\WYZ;'^H.I!&5'IV]LC^?\Q0YPI.,^W^>3^'_
M`->OY-O^"?W_``<(ZA)KWACX.?MY?V0@U^_M=)T7]I#PSIEMHNFZ->78@BL;
M/XS>$;(/::1;7D\T,/\`PG7AP6VG6<DA?7_#>F6$%QK8_I._:&_:.^%G[,GP
M<\3_`!P^*_B*#3?`_AK38[Q'L7@O-3\2W]ZF-%\/>%+,31_VSKFOW#Q6^DVM
MO)LE#FYGFALHKBYB[<!@\9F>-P>79=A<1C<PQ^(HX7!X3"TIUZ^)Q6(JQHT*
M%&E3YISJU:DU&$$KO?1-7Y<;C,+EN$Q.88[$4<)@<'2J8C%8O$5(T</0H48.
MI5JU:DVE"%*"O.3VNK79PG[8O[7WPK_8O^#>K?%WXG7,]V?..C>"O!>E-&WB
M/Q]XPGMY;C3_``WHL3_NX$,<,E]K.KW933M!TBVN=0O9"%AM[C\X/^"7W_!5
MO5?VM?&GB+X"_'G0++PK\<&NO$WC'P!/X=TF_M_"_BGP#'<R:F^@2QR*\VF>
M(?!&E7%M#_:6HK:V_B_11::PD=KJCW-BW\S7[1?[17[0_P#P4J_:4M-?FTK4
M-=U?Q%JUO\/_`(*?`?P[?7-S;^$[#7+FYNM(T+3/,A31I]9GT^Q&O?$7QE?2
M6$+11S7$UW::!HL,5KSWQ`^,>B?LZV3_``"_9:^(EJOQ)TWQ3IFH?M(_M0^#
M;V]M9_'?C_P9>Q:O8?"/X*Z_:^1"/@3\+/&L,4FNZA:R[_C)XUTAM5U0'P7I
MVE6=U_8''7A+X<^"_@Z\#Q[?-?&/BY8?%Y3@\!BO95N%I867,Z=VXQJ9;3I5
M:M',L1*G4CFV/E#"Y:Z4,`\?2_E[@_Q(X[\5/%6G7X,DLN\+^%W4PN:XO&8;
MVM+/95VO>4-'''UE"-3+HPJP^HX6,L3B_:5,0L/5_P!%6)@3\O`(SCCOSGCG
M#'D9]\58K\C/^"1/_!1/7/V^_@IK;^/_``A?Z#\8_@\^@>&OB7XDTK29H/AQ
MXZOM6L[JZTOQ%X6OEC%II^O7UG9->>,/!0(?PSJ%W#+9--HNJ::8OUR7.!GK
M7\:P^%;_`#WUU=_.[[L_JFSC[O;3OITU22V[*RV6B0M%%%4`4UF(Z#/3N!U.
M/T]>GO3JA=L.O!/W>GINQ_.A_JM+7O=VM;1^>FNG:X?=KHK[-]%TWV/CS7O^
M"AG[#_A?6];\-^(OVI_@CI&O^&]6O-"U_2+SQYHZ:AH^LZ=>2Z??Z;J%L)F>
MWN[*^@FM+J*3!@N(GBDVLIKX/_X*#?\`!7#X(?#;]F/QQ>_LG_&SX5_%#X^>
M)X!X1\!6OAWQ;IFJ1^"Y=:MKG^T_B1K$44N/LWA#28KJ]T:U<2#5?%DF@:28
M)X;JX5?Q$_:!_P""0/[6GCGX[?&_QEI?B_\`9EAT+Q9\8_B9XLT'3]5^/.G:
M=?0Z5XC\=:WK]O%JVFR:-YEA?I;7TDFH6?GF:RU$RQ)+L\V6OS#_`&F_V4OB
M5^R1XY\,^#?BMK_P_P!1U/Q+X<F\7Z?J'PR\:IXW\.II]KJ=Q8&WO-8M+"U.
MD:D+BP>2'2Y`V(C%>1W'S[4_NK*?H^?1UQN`R[$XOQTJX?%8G`8+$8K"\^54
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M\UMJ!TA633;B:TAOY6:[B:OK0?\`!&3]K[$CR?$G]DQI&>-WF@_:(TP%01$%
M4BXT%PC0;8?LT<<L2841F81N0_55^CQ]&FG/_D^V)7+\:@LLJW>C;4EA9)M[
MKE@O\*V7%'QO\=Y1C)>#U*HG)VL\RO&.R3;JQ2=MW96U32LS^M63_@I]_P`$
M^[>VMYY/VN/@TEK,DGD2+XDPKK!(8I`!%:\%6`4)M1F#(T8V2(7\/\?V7_!+
M#_@J;)J'PJ?Q1\(?C-\1+/PUK6IZ-XD\!7":9\7_``7IL)@TV^\1>$_%\&G6
MVIVJ:9<ZG9>9;32ZCHMT]Q%%J6EWUI+)#+_,[J/_``1I_:CMD@@7XE_LB201
M1HD+WG[2.CVN9F99II;<-X2;RX!>W,MQ''M\Q\>1("KI*?T\_P""/_\`P3Y^
M.'[,?[7&J_$CXD^,_P!GK7M&E^#?C+PQ'IGPP^,5CXY\31ZAK/B'PG?1W,VA
M6NCZ=*NEI!ILBW.H,S1Q3S6\7DKYJ&OC^._!;P$X?X,S_/.&O%_&YYQ!E^#]
MME>3U(8%0QV)]K3C[&2I8"%3E]FYU')5J7+RKXN96^GX/\6?&'.N)LERK/O"
MZCDV38_&QH9CFG/B_:8'#\DI.K"%2M.,I<RA&S33C*3UL?SY?\%!?V`?BQ^P
M%\7KKX;^-8[GQ=\._%$6MZC\$/B_9:9]GT_Q]H`0K/IGB,6CII^D?$31%O&M
M_$.AW44S26RPZ[H%RVD7,4:_4O[)/Q]T7]KGX+Z7_P`$X/VM_B"VDQ^%KN?6
MOV*OVA/%VJQ6&C_"'XG:9H.J:;IWPA^)^JZI>00^+_ASXAM;C4-!\,:M=6MU
MK/A];VV\+P@R)X:O;/\`M>_:L_99^$7[8?P6\3_`_P",NA_VGX:UY!>:9JUE
M(+3Q+X*\46D<@T7QGX2U109=,\0Z)+-));RH?(OK62[TC4H;S2]0O+.X_P`Z
MG]J_]FWQA^RE\>OB%\`OB%JFF^*M:^']_#9VGBWP?<)=^&]8TV[CBU/PWJ*Q
MQR,^C:\UE>63>)?#&J+/J6EZHDEE';SP_9-0F_DO(L]S7AS.,KX@R+&U,!FN
M4XW#9C@,9A])TL71:G2J<LERU(RMRSIU%*G4IN=*<94YR4OZ/S?*<!GF5X[)
MLVP\<7EN8X:MA<9AZOO1GAZ\;35T_=<=)PG%IPJ)3BU)7/JSXC>(?#?[(7AG
MQ)^SI\/O'GA?Q9^UGXTDO_"'[47Q<\$7%_K'A?X2>#9[.2'7_P!FWX.^,88K
M17\3ZNL=KIGQG^(>E6L%[>6MQ/\`#OP]/'8V?B3[1Y+^P[^Q'\2_V\_C58_!
MOX5Z;'X7\"6-K:ZG\8?B=%975UIOPQ\)7DYA$<[7\>FG6?%6J#398/!WAWR]
M^IZF9-4U.X&DZ-JLA\$_9^^!?B?]H_XQ_"[X$^"-;\.>%_$?Q.\3Q:#HNM>-
M[P>&="CNI;F]NY[FXN>9M0N([`ZE<0Z):37=]KVJ-8:-81S:CJ%NQ_T8OV,?
MV/?A-^Q'\$-!^"WPN@NKV.">36_&_C76]DGBGXC>.;^&*/6O%_B292PCGO7B
M2WTS2;=AI^@Z1!9:1IZ"WM0\GH\6\8<0\>\0X[BCBG'3S+-\R5)U*TX.E2PU
M*$8_5\'A,.Y2CA<-AZ4HT</0H<E.G"E\/M)3D^'ACA?)>#<EP7#W#V"CE^6X
M%5%1HI7K59U*CJ5L1B:J;G6Q%:I+FJU*LI5)-I-J,8Q7I'[/'[/?PO\`V7OA
M)X.^"WP@\/P^'_!7@S38[.U79`VJZUJ$B1G5?$WB6_@@M_[8\3^(+M7U'6]6
MEB26ZNY"J)%:QP6\7MU%%?/'O!1110`5&Q^9<GC&<8]QD^H_K^=24A`/4`_4
M9H?RW6ZNK7UT?E^(:G\$G[2?_!+O]OSQI^T?\?\`QEX:_91^(&M>'O%GQO\`
MBSXB\/:TE]\/)++4=`UOQ]X@U71-5L([_P`9"\CMM1TV]M[Q(KF&V=/M+)):
MP-$4'R=\8?V$/VO?V>O!.H_$GXU?!#Q#\(_A]IEU8Z<?$OC+Q'\+]*T^>_U-
MWMK33(;?3O%-UJ&IZW?R>?+8Z;I%G>W4WSEX9(+:2X@_TB]B?W%_[Y'^%?+G
M[97[*/P^_;2_9Y^(?[/OQ$B%MIWC'2)3X?\`$]M:VUQJ_@3QI8J]SX5\;Z%Y
MZY34M`U58;AHXY(/[0L&O=*GE6UOI\_VIEOTY?$S*\!EV74.%.`9TLMP&"R^
MC.M@^(95*E'`X>EAJ<ZKAQ#3A[2<*2E/DA&"FVXP4;1/Y8QWT2^`L?C<9CJN
M?<74ZV-QE?&5%2QF5<D)XBK*K.%-5,HG:"E.2CS.4E&UY2E>3_SD?`_@/Q%\
M1O$_A7X9^$UT[Q1XR\3ZE:Z-X6\/S>*?!D,VJ^(-58BST/P_=:MKUMHT5[JL
MZ&-;;[9!=7^HS1106YGFCAE^U5_X).?\%"XW./V-/B4L4,?E1"/4?AJ\LD;K
M+&R.C>.#;1"$;V0)]H'^D*\1AF0N/BG]I_\`9D^*_P"Q_P#%G7/@1\:O"AT'
MQSI-P;S2=:T^YNK?0O%/AZTG$>B?$?P%J]Y#;2:AH&K/9PW'_$GNDUCPOK5B
MUCJD.F:C:&&;]^?V%O\`@X4\:_#S0-/^&'[97@7Q)\5M.\.Z7H^GZ+\8_AI%
M9:CX_CL+:RBMHK3Q_P"';RYT[2/%FHB"%+D^*K+5]$UB]Q,FK:7J&M//>/UO
MZ>7B;*5WPEX>I-W<5@^([\S>KNN)8_)66OX8Q^B'P"G_`,E%QG.5])2Q^6QY
M=MHPRN,7M:S23VT/S93_`())_P#!0@;]W['?Q#G:6%S<73S_``YBN7=FMT11
M%_PF[POL9-S[RRM#&CQPK("@_7?_`((N_L*?M4_LX_MAWOQ#^,_[//B_X8>#
MY?@EXW\--XCU>Z\(+IC^(M1\0^$+VVLA#H'B35;R9K^*PO9+3[7;!+=+4R"2
M)YVC?]3_``__`,%T?^"86N>&4\1R?M$OH;'3XM0GT#7_`(9_%"T\3V_F&"*:
MS_LRV\(WHO;ZTDG"7$>E7.H0E8IY[:>XM(C./@W]JS_@XS^#>@>&=6T7]COP
M'XB^*'C*X:>PTOXF?$O0KSP3\+-!'F0JVMIH5W+#X^\5.EK(;K3--FT;PW:W
M4ACDN[]+9#;S?)\=?3`X_P"/>$\\X0S+AO@O!9?GV!G@,3B,OPF?1QE&G.=.
M;GAI8KB#$T85.:E%7G1J+EE)65SW^%/HR\'\(\1Y1Q+@L]XJQ.+R?%PQE##X
M[%8&IA*M6"DHQKPI8"C)P]YZ1DGM:VM_J?\`X*[_`/!532_V+?"__"DO@Y):
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M)\D=$HKEC4FU!U(>]*/[OQ!G$<AR'-LYC@L7F?\`9F7XK&RP.`@ZF,Q,J%'V
MOL*4'9^^N:\HN;I4XN?+*24'_-=\>?@OXK_9R^*6M?#KXB:M;Q:QI%GH/B3P
M]KW@#7KC5?"?C'PQ(T]YI/Q&^%/C7P_=VO\`;7AS4[N"\ETO6+.2RN--\5VK
M:3?66E:OI5_#:?UY_P#!%W_@K?'^TII&B_LK_M+>*8)?VD/#NE3#P#\0=3N]
M/2#X_P#AC2HEDF66>VV6R_%?POIS0Q^)M.#F?Q18Q2>*;19+E-:BM?Y>?AKX
MN^&OQ'^&UI^S3\?=0@T/X8_VQJ&O_!#XUS6$FIO^S9\3-8OHWN]2?^S9)+[5
M?V>?'5P1-\7_``'8RNV@W$D7Q&\+6L.M66I6^J>!>+/A3\3?@C\5=2\%:]!+
M\.OBA\,-7M-=LM?\/:S;V$6BZW:"U\1>'/'W@/Q]93Z1'J/AS7[=-,\3>!O'
M7AZ\CGU[1;^WN[2U>,7=JWW_`(T>#G$?@WQ34R3-5+,<IQLL3B.'.(:5"%'#
M9U@:4H*5.,*3K1I9KAN>G',<%+$3E1]W$4W+#XBC.I\=X7^*&1^*.0+-\M?L
M,RI5(TLYR>357'9;C)2E*I4F]'/"UOWE6A5@^6I"#@U&I2DC_4M!SGV)%+7X
MZ_\`!'7_`(*'>)?VYO@QK.B?$SPUJMI\8_@C;>&O#_C_`,<V$*7OP_\`B7'J
MUG='1/%^D:Q86MOIFE>+=1ATRYD\8^"BD4FEWNS5],#Z)K%E':_L57Y(FI)-
M:IZI]UT?S6I^D>:U3VM?;IVW6H4444P"BBB@`I",XZ\?K[&EHH`^6_VK_P!C
M7]G?]M+X=M\.?V@_`%CXMTRT>YN?#?B*VD.D>./`^I74:PW&K>"?%]FJZQX<
MO9XDCCO5LY_L.IP11VVJV=];((:_EW^-_P#P;8?'7P7?:S>?LM?'GPGX]\%B
M9[O3/!OQ-34_`7Q(_L\1!VT27Q9X>AOO`OBFX+Q):6ESJNA^$+%%D,MXH91L
M_LLHI63UMKW`_P`^)O\`@BM_P4TTS5_[#N?V6HK]KB[-M:ZUH7Q?^%Y\+V?F
MR-+%JEU)<^*K>8QI&S&=XK&,R.%@DLE0QI'])_"'_@WC_;M\;7TP^+'BCX-?
M!71(+@K)/?:]>?$G7;Z(6Y2">T\/^"Q9Z61$;@J]O=>,=+M#+:HLVF:A$([F
M7^XJBE9_S/\`JW^7]:W'KO\`UM_DC\T/V$?^"5_[,_[",+^(_!.GW_C[XSZC
MI?\`9&O?&OQLL$_B:;3Y5B6[TGPKID.[2?`^AW?DQBZL]%0ZEJ"*L6LZQJD<
M-L(OTG>%0N02H7!`&!G!S@G:20>-W]X9!X8U8I&.`?\`/6J[/1M;/T:?K:ZO
M;8-]V]5R[MV6NB5]%J]%8_C[_P""R_\`P2M7X3ZCKW[77[./A?/PLU74[K6O
MCE\.M#TD74GPVU35+J>[U'XD^%[.$-*G@K6=1N6N/&&DVL13PM<O_:UC%'H%
MW>QZ5^>?[%OP1\1_\%"KKPC^R/J^GZ\VJ_#:S'B3X=?M#:=HVG^*#\$OAF^I
MF_\`%_PI^)$=]KFB+XF^#OB^[N'F^&.CV>H?\)1X!^(MR-1\-VMSX1U'Q+86
M/]_6H6MK?VMU8W]K;7UC?6UQ9WUC>01W-G>V=U%Y%S:7EM,KPW-M<02R0SP2
MH\4L;LCJ5)%?/G[.'[*GP&_9*\->)O!_P#\`:9X$T3Q3XJU3QKKL=H\]Y>7^
MK:U=7,Z6TNHWTD]\=%T&V*:3X7T8SFP\/Z1%'8:=%%&&+_T^_I"+B+P/S'PS
MX[X=_P!:LXP-3+J7!O$E?%.C5RNC>?U;$8^K&^+K9AE,(3I86M1ERYAAZOU7
M,N:E3F\3_/B\%?['\6\KXYX/SG_5W`8V&+Q'$N34:'-3Q[BX*I0PT$E1A0Q\
MZJJ5XU/]RJP=;!QO-0IZW[,/[-'PA_9(^#_A7X'_``4\,6_AKP;X7MF:1PJS
M:QXFUV["OK7C#Q7J@1)M9\3Z_=*;O4K^?Y4)CL;"*TTRSLK.W^A.GZ_KS5>`
MD@$DG(7.?^!G/UXJQ7\OQ5E:R2W25W9-75V]WU?F]-#^@]=4]XMQ=MFXMQ;^
+;75OU"BBBF!__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
